Login / Signup

Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancer.

Jing NieHuina WuQian WuLihui LiuKe TangShuo WangJiyong Wu
Published in: Cost effectiveness and resource allocation : C/E (2024)
Pembrolizumab was less cost-effective for patients with platinum-pretreated, recurrent or metastatic NPC compared with chemotherapy in China.
Keyphrases
  • squamous cell carcinoma
  • locally advanced
  • small cell lung cancer
  • advanced non small cell lung cancer
  • papillary thyroid
  • squamous cell
  • rectal cancer
  • chemotherapy induced
  • young adults
  • childhood cancer